Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review
AbstractThe World Health Organization stated on 11 March 2020 that a coronavirus illness had been discovered in Wuhan, China in December 2019. Effective vaccinations are eagerly awaited as the global outbreak of COVID-19 continues. The aim is to evaluate the safety, effectiveness, and immunogenicity...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-10-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2022.2068331 |
| _version_ | 1797272329871425536 |
|---|---|
| author | Neelam Asghar Hassan Mumtaz Abdul Ahad Syed Farea Eqbal Reeju Maharjan Aditya Bamboria Manish Shrestha |
| author_facet | Neelam Asghar Hassan Mumtaz Abdul Ahad Syed Farea Eqbal Reeju Maharjan Aditya Bamboria Manish Shrestha |
| author_sort | Neelam Asghar |
| collection | DOAJ |
| description | AbstractThe World Health Organization stated on 11 March 2020 that a coronavirus illness had been discovered in Wuhan, China in December 2019. Effective vaccinations are eagerly awaited as the global outbreak of COVID-19 continues. The aim is to evaluate the safety, effectiveness, and immunogenicity of Pfizer/AstraZeneca/Modera/Cansino vaccines against COVID-19. An electronic search on different databases yielded 12,907 articles. A total of 20 randomized and non-randomized, published, and ongoing trials were selected. Cochrane RoB version 2.0 was used to assess the authenticity of the studies. Of these 20 trials, three were conducted on Pfizer, three on AstraZeneca, three on Moderna, and two on the Cansino vaccine. These trials have reported promising results for the safety, efficacy, and immunogenicity of the respective vaccines. None of the trials have reported the efficacy and severe adverse outcomes for the Cansino vaccine, hindering its reliability as a safe vaccine against covid-19. Furthermore, the results of these trials have established Pfizer to be the most efficacious vaccine against covid-19, having an efficacy of 94.6%. A few severe adverse events were reported by the included trials. However, further systematic reviews are required to understand the respective vaccine profiles on Immuno-suppressive, organ transplants, and patients with other comorbidities. |
| first_indexed | 2024-03-07T14:26:47Z |
| format | Article |
| id | doaj.art-09be17c5519d4a729fda29cc32ba2ccb |
| institution | Directory Open Access Journal |
| issn | 2578-5826 |
| language | English |
| last_indexed | 2024-03-07T14:26:47Z |
| publishDate | 2022-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj.art-09be17c5519d4a729fda29cc32ba2ccb2024-03-06T06:50:17ZengTaylor & Francis GroupImmunological Medicine2578-58262022-10-0145422523710.1080/25785826.2022.2068331Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic reviewNeelam Asghar0Hassan Mumtaz1Abdul Ahad Syed2Farea Eqbal3Reeju Maharjan4Aditya Bamboria5Manish Shrestha6Clinical Research Center, Shifa International Hospital, Islamabad, PakistanForensic & Toxicology, Riphah International University Rawalpindi, Rawalpindi, PakistanDow University of Health Sciences, Karachi, PakistanDow University of Health Sciences, Karachi, PakistanR-Endocrinology, Hamilton, OH, USAR-Endocrinology, Hamilton, OH, USAR-Endocrinology, Hamilton, OH, USAAbstractThe World Health Organization stated on 11 March 2020 that a coronavirus illness had been discovered in Wuhan, China in December 2019. Effective vaccinations are eagerly awaited as the global outbreak of COVID-19 continues. The aim is to evaluate the safety, effectiveness, and immunogenicity of Pfizer/AstraZeneca/Modera/Cansino vaccines against COVID-19. An electronic search on different databases yielded 12,907 articles. A total of 20 randomized and non-randomized, published, and ongoing trials were selected. Cochrane RoB version 2.0 was used to assess the authenticity of the studies. Of these 20 trials, three were conducted on Pfizer, three on AstraZeneca, three on Moderna, and two on the Cansino vaccine. These trials have reported promising results for the safety, efficacy, and immunogenicity of the respective vaccines. None of the trials have reported the efficacy and severe adverse outcomes for the Cansino vaccine, hindering its reliability as a safe vaccine against covid-19. Furthermore, the results of these trials have established Pfizer to be the most efficacious vaccine against covid-19, having an efficacy of 94.6%. A few severe adverse events were reported by the included trials. However, further systematic reviews are required to understand the respective vaccine profiles on Immuno-suppressive, organ transplants, and patients with other comorbidities.https://www.tandfonline.com/doi/10.1080/25785826.2022.2068331Covid-19vaccinessafetyefficacyimmunogenicity |
| spellingShingle | Neelam Asghar Hassan Mumtaz Abdul Ahad Syed Farea Eqbal Reeju Maharjan Aditya Bamboria Manish Shrestha Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review Immunological Medicine Covid-19 vaccines safety efficacy immunogenicity |
| title | Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review |
| title_full | Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review |
| title_fullStr | Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review |
| title_full_unstemmed | Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review |
| title_short | Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review |
| title_sort | safety efficacy and immunogenicity of covid 19 vaccines a systematic review |
| topic | Covid-19 vaccines safety efficacy immunogenicity |
| url | https://www.tandfonline.com/doi/10.1080/25785826.2022.2068331 |
| work_keys_str_mv | AT neelamasghar safetyefficacyandimmunogenicityofcovid19vaccinesasystematicreview AT hassanmumtaz safetyefficacyandimmunogenicityofcovid19vaccinesasystematicreview AT abdulahadsyed safetyefficacyandimmunogenicityofcovid19vaccinesasystematicreview AT fareaeqbal safetyefficacyandimmunogenicityofcovid19vaccinesasystematicreview AT reejumaharjan safetyefficacyandimmunogenicityofcovid19vaccinesasystematicreview AT adityabamboria safetyefficacyandimmunogenicityofcovid19vaccinesasystematicreview AT manishshrestha safetyefficacyandimmunogenicityofcovid19vaccinesasystematicreview |